|
"peng c y"的相關文件
顯示項目 201-225 / 360 (共15頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; Kao J.-H.; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-03-09T01:43:13Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; TUNG-HUNG SU; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:12Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; TUNG-HUNG SU; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-02-02T02:48:04Z |
Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients
|
Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU; Peng C.-Y.; Wu Y.-Y. |
| 臺大學術典藏 |
2021-01-14T03:08:53Z |
General and abdominal adiposity and risk of death in HBV versus non-HBV carriers: A 10-year population-based cohort study
|
Lin W.-Y.; Peng C.-Y.; Lin C.-C.; Davidson L.E.; Pi-Sunyer F.X.; Sung P.-K.; KUO-CHIN HUANG |
| 國立成功大學 |
2021 |
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
|
Teng, W.;Chang, T.-T.;Yang, H.-I.;Peng, C.-Y.;Su, C.-W.;Su, T.-H.;Hu, T.-H.;Yu, M.-L.;Yang, H.-C.;Wu, J.-C. |
| 國立成功大學 |
2021 |
Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury
|
Huang, Y.-S.;Chang, T.-T.;Peng, C.-Y.;Lo, G.-H.;Hsu, C.-W.;Hu, C.-T.;Huang, Y.-H. |
| 國立成功大學 |
2021 |
Chaos-based secure communications in biomedical information application
|
Liao, T.-L.;Chen, H.-C.;Peng, C.-Y.;Hou, Y.-Y. |
| 國立成功大學 |
2021 |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang, C.-F.;Kuo, H.-T.;Chang, T.-S.;Lo, C.-C.;Hung, C.-H.;Huang, C.-W.;Chong, L.-W.;Cheng, P.-N.;Yeh, M.-L.;Peng, C.-Y.;Cheng, Cheng C.-Y.;Huang, J.-F.;Bair, M.-J.;Lin, C.-L.;Yang, C.-C.;Wang, S.-J.;Hsieh, T.-Y.;Lee, T.-H.;Lee, P.-L.;Wu, Wu W.-C.;Lin, C.-L.;Su, W.-W.;Yang, S.-S.;Wang, C.-C.;Hu, J.-T.;Mo, L.-R.;Chen, Chen C.-T.;Huang, Y.-H.;Chang, Chang C.-C.;Huang, C.-S.;Chen, G.-Y.;Kao, C.-N.;Tai, C.-M.;Liu, C.-J.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Kao, J.-H.;Lin, H.-C.;Chuang, W.-L.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh, M.-L.;Hung, C.-H.;Tseng, K.-C.;Lai, H.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Tsai, P.-C.;Peng, C.-Y.;Liu, C.-J.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh, M.-H.;Bair, M.-J.;Tsai, P.-C.;Tseng, K.-C.;Lo, C.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Hung, C.-H.;Lai, H.-C.;Peng, C.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Tai, C.-M.;Lin, C.-W.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Yeh, M.-L.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Yu, M.-L.;Chuang, W.-L.;investigators, T-COACH |
| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan
|
Huang, Y.-S.;Wu, C.-Y.;Chang, T.-T.;Peng, C.-Y.;Lo, G.-H.;Hsu, C.-W.;Hu, C.-T.;Huang, Y.-H. |
| 國立成功大學 |
2021 |
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng, P.-N.;Chen, Chen C.-Y.;Yu, M.-L.;Lin, C.-C.;Lin, C.-Y.;Peng, C.-Y.;Tseng, K.-C.;Lo, C.-C.;Tseng, I.-H.;Liu, C.-J. |
| 國立成功大學 |
2021 |
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
|
Hsu, W.-F.;Tsai, P.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Lai, H.-C.;Kuo, H.-T.;Hung, C.-H.;Tung, S.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Lin, C.-Y.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Yu, M.-L.;Peng, C.-Y. |
| 國立成功大學 |
2021 |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
Hsu, Y.-C.;Yeh, M.-L.;Wong, G.L.-H.;Chen, Chen C.-H.;Peng, C.-Y.;Buti, M.;Enomoto, M.;Xie, Q.;Trinh, H.;Preda, C.;Liu, Liu L.;Cheung, K.-S.;Yeo, Yeo Y.H.;Hoang, J.;Huang, C.-F.;Riveiro-Barciela, M.;Kozuka, R.;Istratescu, D.;Tsai, P.-C.;Accarino, E.V.;Lee, D.-H.;Wu, J.-L.;Huang, J.F.;Dai, C.-Y.;Cheung, R.;Chuang, W.-L.;Yuen, M.-F.;Wong, V.W.-S.;Yu, M.-L.;Nguyen, M.H. |
| 國立成功大學 |
2021 |
Research on information management analysis of battery efficiency data
|
Peng, C.-Y.;Wu, S.-D.;Lin, Y.-C.;Chuang, H.-Y. |
| 臺大學術典藏 |
2020-12-28T08:14:08Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Hu T.-H.; Huang Y.-H.; Chen C.-H.; Liu C.-J.; Peng C.-Y.; Kao J.-H.; Chien R.-N.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:55Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:23Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J.; Liu C.-J.; Chang J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B. |
| 臺大學術典藏 |
2020-11-03T08:19:41Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Kao J.-H.; Chen D.-S.; Chen P.-J.; Tseng T.-C.; Su T.-H.; Liu C.-J.; CHEN-HUA LIU; Yang S.-S.; Peng C.-Y.; Lin W.-T. |
| 臺大學術典藏 |
2020-11-03T08:19:41Z |
2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2020-11-03T08:19:40Z |
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-J.; CHEN-HUA LIU; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L.; Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H. |
顯示項目 201-225 / 360 (共15頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目
|
